Payment overview · 2025
General Payments
$2,724.64
113 reported records · 23 companies
Healthcare provider profile · identity verified
Tracy Vo, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE CORAL, FL · NPI 1598708430
Verified facts
What the public records show
CMS Open Payments records show Tracy Vo, DO received $2,724.64 in general payments during 2025 across 113 reported records.
Lilly USA, LLC accounted for 10.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $285.56 | 10.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $238.09 | 8.7% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $194.92 | 7.2% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.08 | 6.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $174.15 | 6.4% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $159.15 | 5.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.09 | 5.8% | 9 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $146.41 | 5.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $146.15 | 5.4% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.29 | 5.3% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $120.54 | 4.4% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $119.67 | 4.4% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $107.50 | 4.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.84 | 3.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.19 | 3.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.02 | 3.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.87 | 2.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $73.76 | 2.7% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $41.75 | 1.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.12 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.60 | 0.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.53 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.36 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,624.65 | 111 |
| Education | $99.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $228.57 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $221.00 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.49 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $171.32 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $167.36 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $155.21 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $146.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $122.53 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $120.54 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.18 | 6 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $107.50 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $103.84 | 5 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $102.39 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $99.30 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $82.02 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.98 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.90 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $74.87 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $74.35 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $74.16 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $73.76 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.69 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.31 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.31 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.46 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.82 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.91 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.60 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 65 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 182 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 97 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 97 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
182 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 582 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 569 | 160 |
| Losartan Potassium | Losartan Potassium | 497 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 108 |
| Gabapentin | Gabapentin | 312 | 102 |
| Lisinopril | Lisinopril | 300 | 92 |
| Alprazolam | Alprazolam | 287 | 67 |
| Simvastatin | Simvastatin | 287 | 82 |
| Metformin Hcl | Metformin Hcl | 286 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 246 | 54 |
| Omeprazole | Omeprazole | 228 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 70 |
| Trazodone Hcl | Trazodone Hcl | 212 | 59 |
| Meloxicam | Meloxicam | 185 | 56 |
| Mounjaro | Tirzepatide | 182 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 47 |
| Montelukast Sodium | Montelukast Sodium | 142 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 142 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 55 |
| Buspirone Hcl | Buspirone Hcl | 122 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 38 |
| Mirtazapine | Mirtazapine | 118 | 34 |
| Ezetimibe | Ezetimibe | 117 | 42 |
| Clonazepam | Clonazepam | 115 | 23 |
| Lorazepam | Lorazepam | 111 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 33 |
| Atenolol | Atenolol | 101 | 33 |
| Furosemide | Furosemide | 98 | 36 |
| Rybelsus | Semaglutide | 97 | 20 |
| Synthroid | Levothyroxine Sodium | 97 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 53 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 95 | 29 |
| Carvedilol | Carvedilol | 90 | 30 |
| Famotidine | Famotidine | 90 | 37 |
| Spironolactone | Spironolactone | 90 | 25 |
| Estradiol | Estradiol | 88 | 34 |
| Ozempic | Semaglutide | 88 | 22 |
| Glimepiride | Glimepiride | 85 | 23 |
| Sertraline Hcl | Sertraline Hcl | 81 | 27 |
| Allopurinol | Allopurinol | 80 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 68 |
| Bupropion Xl | Bupropion Hcl | 74 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 19 |
| Baclofen | Baclofen | 68 | 24 |
| Potassium Chloride | Potassium Chloride | 68 | 20 |
| Eliquis | Apixaban | 65 | 18 |
| Farxiga | Dapagliflozin Propanediol | 63 | 16 |
| Azithromycin | Azithromycin | 62 | 54 |
| Chlorthalidone | Chlorthalidone | 59 | 20 |
| Valacyclovir | Valacyclovir Hcl | 55 | 25 |
| Celecoxib | Celecoxib | 52 | 18 |
| Methylprednisolone | Methylprednisolone | 49 | 42 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Lovastatin | Lovastatin | 48 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 16 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Irbesartan | Irbesartan | 46 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 45 | 17 |
| Nifedipine Er | Nifedipine | 45 | 13 |
| Sucralfate | Sucralfate | 45 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 45 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 14 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | 12 |
| Tramadol Hcl | Tramadol Hcl | 40 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 39 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | 14 |
| Torsemide | Torsemide | 38 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 32 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Prednisone | Prednisone | 35 | 23 |
| Valsartan | Valsartan | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Alendronate Sodium | Alendronate Sodium | 32 | 14 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Nystatin | Nystatin | 28 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Meclizine Hcl | Meclizine Hcl | 21 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Mupirocin | Mupirocin | 14 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 12 | 11 |
| Estazolam | Estazolam | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 12 | suppressed |
| Osphena | Ospemifene | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,724.64 · 113 records | Lilly USA, LLC | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, Barostim Neo System, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FFRct, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, LEQVIO, MITRACLIP, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, UBRELVY, VRAYLAR, VYEPTI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error